Studying outcomes after CAR-T, radiation, or bispecific therapy
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how people with blood cancers do after they receive CAR-T therapy, radiation therapy, and/or bispecific therapy. It may help doctors understand which treatment combinations work best and what side effects to expect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have a blood cancer (a hematologic malignancy)
- You are getting, or plan to get, radiation therapy
- You have received (or plan to receive) standard-of-care CAR-T cell therapy
- You have received (or plan to receive) standard-of-care bispecific therapy
- These treatments happen within 90 days of each other
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children and young adults who received CAR T cell therapy to understand any long-term side effects that may appear months to years later. By joining, you help researchers learn how to better care for patients after this treatment.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study is for people with blood cancers who are treated with CAR-T cell therapy. Researchers will follow participants over time to learn more about how this therapy works in the real world.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
This study looks at how CAR-T therapy affects blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas/leukemias. You will provide biological samples to help researchers understand these effects.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
Hear when a new Hematopoietic and Lymphoid Cell Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.